Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix and Toppan Printing to Develop and Market Microarrays

CombiMatrix said today that it has formed a strategic alliance with Toppan Printing to develop and manufacture microarrays that use electrochemical detection.

 

Toppan of Tokyo, Japan, will pay CombiMatrix, a subsidiary of Acacia Research, an upfront fee of $1 million as well as additional development and milestone fees. Toppan will manufacture microarrays for CombiMatrix and its partners and share revenues and royalties on these.

 

The two companies plan to co-develop semiconductor microarrays for applications in research and diagnostics. Unlike microarrays that CombiMatrix has developed in collaboration with Roche, which use optical detection, these arrays will rely on electrochemical detection.

 

CombiMatrix said it has already tested this technology in small prototype instruments and assays for biological and chemical defense applications.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.